Home
Loading

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

Get in touch

  • Contact

  • Request a demo

  • Request data updates

  • Add a company

Research

  • Companies

  • Investors

  • People

aVenture

  • Sitemap

  • Feature requests

Member

Backed by

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy Policy

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading homepage
Loading
Loading
Loading
Home›
Research›
Investment Firms›
Casdin Capital
AddedFeb 13, 2024
UpdatedJul 16, 2026
Casdin Capital

Casdin Capital

Operating

Casdin Capital, LLC: A US-based investment firm specializing in life sciences, biotech, and pharma sectors.

Location
New York City, NY, US
Founded
2012
Firm
Compare
Portfolio
Employees
Website

Investments

Flare Therapeutics
Flare Therapeutics
Series C

Total Raised

$290M

Rounds

3

Series C$85MJune 2026
Series B$123MMarch 2023
Remix Therapeutics
Remix Therapeutics

Total Raised

$211M

Rounds

4

Series Unknown$60MJanuary 2024
Series B$70MMay 2022
Rome Therapeutics
Rome Therapeutics

Total Raised

$199M

Rounds

3

Series B$72MSeptember 2023
Thyme Care
Thyme Care

Total Raised

$82M

Rounds

2

Series B$60MAugust 2023
Octave Bioscience
Octave Bioscience

Total Raised

$91M

Rounds

6

Series B$32.5MJuly 2023
Septerna
Septerna

Total Raised

$250M

Rounds

2

Series B$150MJuly 2023
Orbital Therapeutics
Orbital Therapeutics

Total Raised

$270M

Rounds

2

Series A$270MApril 2023
Function Oncology
Function Oncology

Total Raised

$28M

Rounds

1

Series A$28MApril 2023
Chroma Medicine
Chroma Medicine

Total Raised

$260M

Rounds

3

Series B$135MMarch 2023
iVexSol
iVexSol

Total Raised

$39M

Rounds

4

Series A$23.8MJanuary 2023
Nest Genomics
Nest Genomics
Seed

Total Raised

$9M

Rounds

2

Seed$8.5MJanuary 2023
Asimov
Asimov

Total Raised

$205M

Rounds

4

Series B$175MJanuary 2023
Vector Biomed
Vector Biomed

Total Raised

$15M

Rounds

1

Series Unknown$15MDecember 2022
Fog Pharmaceuticals
Fog Pharmaceuticals

Total Raised

$385.3M

Rounds

5

Series D$178MNovember 2022
LetsGetChecked
LetsGetChecked

Total Raised

$393M

Rounds

6

Series D$20MSeptember 2022
Idrx
Idrx

Total Raised

$122M

Rounds

1

Series A$122MAugust 2022
Auron Therapeutics
Auron Therapeutics

Total Raised

$61.4M

Rounds

3

Series A$48MJuly 2022
Character Biosciences
Character Biosciences

Total Raised

$27M

Rounds

4

Series A$18MMay 2022
Invetx
Invetx

Total Raised

$85.8M

Rounds

3

Series B$60.5MMay 2022
Moma Therapeutics
Moma Therapeutics

Total Raised

$236M

Rounds

2

Series B$150MMay 2022
Arzeda
Arzeda

Total Raised

$66.4M

Rounds

11

Series B$33MMarch 2022
Celsius Therapeutics
Celsius Therapeutics

Total Raised

$148M

Rounds

2

Series B$83MMarch 2022
Deepcell
Deepcell

Total Raised

$98M

Rounds

4

Series B$73MMarch 2022